Semaglutide research: mechanism, trials, and what they measured

Before the details

Here is the Semaglutide research in plain terms. Semaglutide copies GLP-1, a hormone your gut releases after a meal. GLP-1 normally tells the pancreas to release insulin when blood sugar is high, tells it to ease off a hormone called glucagon, slows how fast the stomach empties, and signals the brain that you are full. Natural GLP-1 is gone in about two minutes; semaglutide is built to last about a week, which is why it can be dosed once a week.

The trials are large and consistent. People taking it lose meaningful weight, their blood sugar improves, and in high-risk groups it lowers the chance of heart attack, stroke and serious kidney problems. A 2025 head-to-head trial found a newer drug, tirzepatide, produced somewhat more weight loss. The studies below give the exact numbers, and each one names the trial it came from.

What is semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a medicine that switches on the same receptor as the natural gut hormone GLP-1. Structurally it is a 31-amino-acid analogue of human GLP-1 with about 94% of the same sequence. Two deliberate changes make it last: a substitution at position 8 (alpha-aminoisobutyric acid in place of alanine) blocks the enzyme DPP-4 that normally chews up GLP-1 within minutes, and a fatty-acid chain attached to the peptide binds tightly but reversibly to albumin, the most abundant protein in blood, which shields the drug from being filtered out by the kidneys. Together these give an elimination half-life of about one week. It is supplied as a once-weekly subcutaneous injection and as a once-daily oral tablet.

How does semaglutide work

Semaglutide activates GLP-1 receptors throughout the body, and the effects split between the pancreas, the gut and the brain. At the pancreas it boosts insulin release in a glucose-dependent way (it acts when blood sugar is high, which keeps the risk of low blood sugar low) and suppresses glucagon, the hormone that raises blood sugar. In the gut it slows stomach emptying. Its weight effect, though, is mostly in the brain.

A mechanistic study in rodents mapped how it gets there: semaglutide directly accessed the brainstem, the area postrema, the hypothalamic arcuate nucleus and the parabrachial nucleus — appetite-control regions — reduced food intake and shifted food preference, all without lowering energy expenditure ^[4]. In plain terms, it turns down hunger signaling rather than speeding up calorie burn. The arcuate nucleus is a small hub in the hypothalamus holding both "I'm full" neurons (POMC/CART) and "I'm hungry" neurons (NPY/AgRP); semaglutide turns up the first and turns down the second.

Semaglutide weight loss

The weight-loss evidence is anchored by the STEP program. In STEP 1, once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline to week 68, versus -2.4% with placebo, in adults with overweight or obesity and no diabetes — a treatment difference of about 12.4 percentage points ^[1]. Alongside the weight change, semaglutide improved multiple cardiometabolic risk factors — waist circumference, blood pressure, lipids, blood sugar and inflammatory markers — versus placebo ^[11].

The durability data come with an honest caveat: the effect depends on continued treatment. In the STEP 1 trial extension, participants who stopped regained a mean of about 11.6 percentage points of body weight within a year, and the cardiometabolic gains reverted toward baseline ^[15]. That regain pattern is why obesity pharmacotherapy is framed as a chronic, ongoing intervention rather than a one-time cure.

The cardiovascular and kidney trials

Two large outcome trials moved semaglutide beyond blood-sugar and weight endpoints. In SUSTAIN-6, once-weekly semaglutide (0.5 or 1.0 mg) reduced the composite of cardiovascular death, nonfatal heart attack or nonfatal stroke by a hazard ratio of 0.74 (95% CI 0.58–0.95) in type 2 diabetes at high cardiovascular risk — though the same trial recorded higher rates of diabetic-retinopathy complications (HR 1.76; 95% CI 1.11–2.78) ^[2]. SELECT then tested the cardiovascular question in people without diabetes: across 17,604 adults with established cardiovascular disease and obesity, semaglutide 2.4 mg cut major adverse cardiovascular events by 20% (HR 0.80; 95% CI 0.72–0.90) ^[3].

The kidney evidence comes from FLOW, in 3,533 people with type 2 diabetes and chronic kidney disease: once-weekly semaglutide 1.0 mg reduced major kidney-disease events — kidney failure, a 50%-or-greater drop in kidney filtration, or kidney or cardiovascular death — by 24% (HR 0.76; 95% CI 0.66–0.88) ^[6]. A clinical pharmacokinetics study also found semaglutide had no clinically relevant effect on the levels of co-administered metformin, warfarin, atorvastatin or digoxin, indicating a low drug-interaction risk despite the delayed stomach emptying ^[12].

Semaglutide vs tirzepatide

The most direct comparison is SURMOUNT-5, a 2025 head-to-head trial in 751 adults with obesity. Tirzepatide — a dual agonist that hits both the GIP and GLP-1 receptors, where semaglutide hits GLP-1 alone — produced greater mean weight loss at 72 weeks: -20.2% versus -13.7% for semaglutide, an advantage of about 6.5 percentage points, statistically significant at P<0.001 ^[7].

That result places semaglutide as a highly effective single-receptor agonist that a dual-agonist can exceed on the weight endpoint. It does not, on its own, settle questions of tolerability, cardiovascular and kidney outcomes, or access — areas where semaglutide carries the larger long-term outcome dataset (SELECT and FLOW). The comparison is one endpoint, in one population, at one time point; the broader evidence base is what this site documents.

Comparative diabetes trials

Within the GLP-1 class, semaglutide has compared favourably in its diabetes trials. In SUSTAIN 7, once-weekly semaglutide produced greater reductions in HbA1c (a three-month average of blood sugar) and body weight than once-weekly dulaglutide in type 2 diabetes ^[9]. On the oral side, PIONEER PLUS found that higher-dose oral semaglutide (25 mg and 50 mg) improved both glycemic control and body weight versus the 14 mg dose in type 2 diabetes inadequately controlled on prior therapy ^[10]. These comparative data sit underneath the headline outcome trials and help define where semaglutide lands among its peers.